Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities research analysts at Zacks Research lowered their Q3 2025 earnings estimates for Agios Pharmaceuticals in a report released on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.80) for the quarter, down from their previous estimate of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period last year, the business earned ($1.51) EPS. The firm’s revenue was up 28.4% compared to the same quarter last year.
Read Our Latest Stock Report on Agios Pharmaceuticals
Agios Pharmaceuticals Trading Up 1.7 %
AGIO stock opened at $45.08 on Friday. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $53.28. The company has a market capitalization of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75. The firm has a 50 day simple moving average of $44.64 and a 200-day simple moving average of $41.46.
Hedge Funds Weigh In On Agios Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Caxton Associates LP boosted its holdings in shares of Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after acquiring an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after acquiring an additional 540 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $37,000. Finally, Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $40,000.
Insider Activity at Agios Pharmaceuticals
In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
- Five stocks we like better than Agios Pharmaceuticals
- CD Calculator: Certificate of Deposit Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Following Congress Stock Trades
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- The How and Why of Investing in Gold Stocks
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.